echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The market continues to expand, and pharmaceutical companies are accelerating their entry into the CRO field

    The market continues to expand, and pharmaceutical companies are accelerating their entry into the CRO field

    • Last Update: 2022-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    CRO, that is, pharmaceutical R&D and production outsourcing
    .
    The research and development of a new drug, from drug discovery, preclinical research to clinical stage research, involves many links, requires very large funds and R&D teams, and is not efficient
    .
    Therefore, with the rapid development of the pharmaceutical industry and the introduction of regulatory regulations, many pharmaceutical companies choose to outsource certain businesses, which has spawned and accelerated the rise and development
    of the CRO industry.

     
    It is understood that in recent years, in the context of the continuous deepening of domestic medical reform, the consistency evaluation of generic drugs has opened the market access and reshuffle of existing pharmaceutical products, and the priority review and approval, drug marketing authorization holder system greatly encourages the innovation and upgrading of the entire industry and the professional division of labor, the CRO industry is ushering in huge development opportunities
    .

     
    According to Frost & Sullivan, the global CRO market size will be about $73.
    1 billion in 2021, with a CAGR of about 9.
    5%
    from 2021 to 2024.
    Among them, in China, the scale of China's CRO market has reached about 10 billion US dollars in 2021, with a CAGR of about 30.
    3%
    from 2021 to 2024.
    Among them, the market size of clinical CRO in 2021 is about 5.
    6 billion US dollars, with a CAGR of about 34.
    7%
    from 2021 to 2024.
    It is worth noting that in the context of the continuous improvement of CRO development, many pharmaceutical companies have begun to accelerate their entry into this field
    .

     
    Recently, Harbour Biopharma announced that it entered into an asset transfer agreement with WuXi Hyde to sell the production plant of the Biomacromolecule R&D Innovation Center project for a total consideration of RMB 146 million
    .
    It is understood that in the announcement of the sale of assets by Harbour Biologics, it was mentioned that the transaction amount of 146 million yuan was paid in four tranches, and the last payment of 14.
    6 million yuan was based on the CDMO agreement
    between Harbour Pharma and WuXi Hyde (the announcement stated that it was "buyer or contact", most likely WuXi Biologics).

     
    In September, in the transaction between Kexi Biologics and WuXi Biologics, Kexi Biologics not only sold the factory to Biologics, but also became the exclusive CDMO partner
    of Kexi Biologics in the future.

     
    In addition, in addition to pharmaceutical companies, many domestic companies are also accelerating the layout of CRO, such as JD Health has already begun to deploy clinical CRO, in 2021 launched the "Clinical Trial Patient Recruitment Center", has been with nearly 20 CRO companies and related clinical research institutions including Kanglong Chemical, Houpu Pharmaceutical, Home Credit Pharmaceutical, Aisha Medical, etc.
    , to carry out multi-dimensional clinical trial patient recruitment business cooperation, in about 1 year, Served more than 400 Phase I-III clinical trials in ongoing R&D
    .

     
    Industry insiders believe that in the long run, the growth of pharmaceutical R&D investment and the increase in R&D outsourcing rate will drive the continuous expansion of the CRO industry, while the improvement of the domestic innovative drug R&D environment will also benefit the development of
    upstream CRO enterprises.
    Based on the optimism of the market, the layout of pharmaceutical companies in the CRO field will also be more frequent and diversified
    .

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.